Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01

Exclusion Criteria

• •Current controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis, based on the Neurodevelopment Intake Form, Behavior Assessment System for Children (BASC), and subsequent clinical interviewing, with significant symptoms including but not limited to post-traumatic stress disorder, psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments. (Participants with clinical history of learning disorders will be allowed to participate as long as the disorder does not impact their ability to participate based on PI judgement).
• •Autism Spectrum Disorder concern as indicated from the Social Communication Questionnaire ≥ 15.
• •Current treatment with stimulant treatment for ADHD and unwilling or inappropriate (per investigator opinion) to washout.
• •Initiation or completion of behavioral therapy within the last 4 weeks. The participant should inform the Investigator if they intend to change their behavioral therapy during the 4 weeks of the study. Participants who have been in behavior therapy consistently for more than 4 weeks may participate if their routine is unchanged throughout the study.
• •Participant is currently considered at risk for attempting suicide by the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation or self-injurious behavior, as measured by MINI-KID Suicidality Module C.
• •Motor condition (e.g. physical deformity of the hands/arms) that prevents game playing as reported by the parent or observed by the Investigator.
• •Recent history or suspicion (within the past 6 months) of substance abuse or dependence.
• •History of seizures (excluding febrile seizures).
• •Participation in a clinical trial within 90 days prior to screening.
• •Color blindness as detected by Ishihara Color Blindness Test.
• •Regular use of psychoactive drugs that in the opinion of the Investigator may confound study data/assessments.
• •Any other medical condition that in the opinion of the Investigator may confound study data/assessments.
• •Previously received AKL-T01 (Project-EVO™) treatment in a previous clinical trial.
• •Concurrent brain training